Search
Parathyroid hormone
go.drugbank.com/drugs/DB05829ApprovedInvestigationalPreos is a registered trade mark owned by NPS Pharmaceuticals, Inc. The name Preos and the New Drug Application is pending approval by the U.S. Food and Drug Administration (FDA). … Preotact is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures and is marketed in Europe by Nycomed.
Rimonabant
go.drugbank.com/drugs/DB06155ApprovedWithdrawnRimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. … This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression.
Cetilistat
go.drugbank.com/drugs/DB06586InvestigationalCetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.
Dirithromycin
go.drugbank.com/drugs/DB00954InvestigationalDirithromycin is a macrolide glycopeptide antibiotic used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections.
Flupirtine
go.drugbank.com/drugs/DB06623InvestigationalIt is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.
Etravirine
go.drugbank.com/drugs/DB06414ApprovedInvestigationalEtravirine does not inhibit human DNA polymerase alpha, beta or gamma. … Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI).
Categories: Non-Nucleoside Reverse Transcriptase Inhibitors, Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase InhibitorDiethylpropion
go.drugbank.com/drugs/DB00937ApprovedIllicitInvestigationalA appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. … It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290)
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeNOV-002
go.drugbank.com/drugs/DB05393InvestigationalNOV-002 is approved and marketed in the Russian Fereration by Pharma BAM under the trade name Glutoxim. … NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy.
R673
go.drugbank.com/drugs/DB05466ExperimentalThe phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but SP levels have been commonly linked to the functioning … of limbic system with respect to anxiety and depression.